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Research
of many countries because of concerns
and public perceptions about the reac-
togenicity of the whole-cell product.
Clinical trials and passive surveillance
data have shown that vaccines contain-






revieMJA Vol 179 18 August 2003ABSTRACT
Objective:  To assess the reported rate of local reactions after administration of 
ular pertussis vaccine (DTPa) according to dose number and type of pertussis 
ine (whole-cell or acellular) used for the primary course, and to document the 
rity and outcome of fourth-dose local reactions.
gn and setting:  Retrospective review. Reports of adverse events after 
ination in South Australia between 1 January 1997 and 31 December 2000 were 
wed, and a questionnaire administered to all parents who reported a local 
reaction after the fourth dose of DTPa.
Main outcome measures:  The number, and rate per 100 000 administered doses, 
of local reactions following the primary and booster doses of DTPa, and of local 
reactions after the fourth-dose in cohorts of children whose primary vaccinations were 
with either DTPw or DTPa. Redness and/or swelling at the injection site as reported by 
parents.
Results:  Of 581 reported adverse events after vaccination, 138 were local reactions 
after a pertussis-containing vaccine. Primary vaccinations with DTPa was a significant 
risk factor for a fourth-dose local reaction (relative risk, 6.7; 95% CI, 2.4–18.5). 
Parental questionnaires were completed for 45 of the 71 children (63%) with reported 
local reactions after the fourth dose of DTPa; extensive limb swelling was reported 
in 8 children (18%) and all except one child had recovered by the time of review.
Conclusions:  Parents should be informed that children receiving booster doses of 
DTPa vaccine, after primary doses with DTPa, are at increased risk of local reactions 
(which tend to resolve spontaneously) but not of systemic effects. Studies should be 
initiated to investigate the pathogenesis and the risk of recurrence of local reactions 
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to further improve vaccination schedules.ACELLULAR PERTUSSIS VACCINES
have now replaced whole-cell pertussis
vaccine in the immunisation schedules
reactogenic than whole-cell pertussis
vaccines.1-5
In August 1997, an acellular combina-
tion diphtheria–tetanus–pertussis vac-
cine (DTPa [Infanrix, GlaxoSmithKline,
Melbourne]) was introduced into South
Australia to replace the previous whole-
cell pertussis-containing vaccine (DTPw
[Triple Antigen, CSL Limited, Mel-
bourne]). All children receiving their pri-
mary vaccinations after August 1997
were given DTPa vaccine, as were all
children presenting for booster doses at
18 months and 4–5 years of age; by April
1998 distribution of DTPw vaccine in
SA had reduced markedly. The Austral-
ian Standard Vaccination Schedule
changed from whole-cell to acellular per-
tussis vaccine from May 2000 (Box 1).
After DTPa vaccine was introduced, a
significant decrease in the reported rates
of both local and general adverse events
was noted, but more recently there has
been an increase in the number of
reported local reactions after DTPa
administration.8
We examined, firstly, the passive sur-
veillance data to compare the rates of
local reactions according to the dose
number, and to compare such rates
after the fourth dose between cohorts of
children whose primary vaccinationswere with DTPw and with DTPa. Sec-
ondly, we ascertained the severity and




Since the passive surveillance scheme
was established in 1996, medical practi-tioners and vaccination providers have
been asked to report any serious and/or
unexpected adverse event after vaccina-
tion to the South Australian Immunisa-
tion Coordination Unit (SAICU).
Reports are received on a standard form,
which asks for demographic details, the
suspected vaccine, concomitant vaccines
administered, and details of the event,
including time to recovery and treat-
ment required. At the SAICU all reports
are reviewed by a paediatrician with an
interest in vaccine safety (M G), and the
adverse event is classified according to
the definitions in Box 2.
If the reported adverse event meets
the case definition of a serious “adverse
event following immunisation” accord-
ing to the Australian immunisation hand-
book,7 details are forwarded to the
national Adverse Drug Reaction Assess-
ment Committee (ADRAC).191
RESEARCHFor this study, all reports of a local
reaction, skin rash, hypotonic hypo-
responsive episode or seizure associated
with the administration of a pertussis-
containing vaccine, received between 1
January 1997 and 31 December 2000,
were included.
Before August 1997, only DTPw was
distributed. This was replaced with
DTPa between August 1997 and
December 1998.
For the purpose of analysing the effect
of having had primary vaccinations with
DTPw or DTPa, the reported rates of
adverse events after the fourth dose of
DTPa were compared in two groups as
follows:
DTPw primary vaccination group:
children whose reactions to the fourth
dose occurred before January 1999 were
assumed to have received DTPw for
their first, second and third doses. This
group of children would have received
their third dose of DTP vaccine before
June 1997, when DTPw was the only
DTP vaccine available.
2: Classification of adverse events aft
Australian Immunisation Coordinati
Local reaction: redness and/or swelling (without 
the vaccine site.
Serious local reaction: redness and/or swelling a
redness and swelling lasting more than 3 days, (
extending from the injection site beyond one or b
limb from joint to joint.
Extensive limb swelling: swelling extending from 
swelling of the entire proximal limb from joint to j
Skin rash: any skin eruption (erythema, urticaria,
Seizure: sudden loss of consciousness with mot
occurring within 7 days of vaccination.
Hypotonic hyporesponsive episode: an event of s
immunisation and presenting with hypotonia, hyp
failure of the observer to recall any change in sk
1: Australian Standard Vaccination Sc
Age of child Vaccines given before May 2
Birth
2 months DTP, Hib, OPV
4 months DTP, Hib, OPV
6 months DTP, Hib, OPV
12 months MMR
18 months DTP, Hib
4 years DTP, MMR, OPV
Hep-B = hepatitis B vaccine; DTP = diphtheria–tetanus–
DTPa = diphtheria–tetanus–pertussis vaccine (acellular
influenzae type b vaccine; MMR = measles–mumps–rub
tetanus–pertussis (acellular) and hepatitis B vaccine.192DTPa primary vaccination group:
children whose reactions to the fourth
dose occurred from June 1999 were
assumed to have received DTPa for
their first, second and third doses.
These children would have received
their third dose of DTP vaccine after
June 1998, 10 months after DTPa was
introduced.
The Australian Childhood Immunisa-
tion Register (ACIR), which was estab-
lished in January 1996 to record all
vaccines administered to Australian
children under 7 years of age from data
provided by vaccine providers, was used
to estimate the number of administered
doses of DTPa.10
From 1 January 1998 to 31 Decem-
ber 2000, reports of any fourth-dose
local reaction after DTPa vaccine
administration were identified. At the
time of submitting the report of an
adverse event after vaccination to
SAICU, all parents routinely provide
written consent to be contacted. Three
attempts were made to contact the par-
er vaccination, used by the South 
on Unit
abscess formation) occurring within 7 days at 
t the injection site AND at least one of: (i) pain, 
ii) hospitalisation, (iii) redness and/or swelling 
oth joints, or (iv) redness of the entire proximal 
the injection site beyond one or both joints or 
oint.
 or angioedema).
or or sensory symptoms or signs, both 
udden onset occurring within 48 hours of 
oresponsiveness and pallor or cyanosis or 
in colouration.9
hedule used in South Australia








pertussis vaccine (acellular or whole cell); 
); OPV = oral polio vaccine; Hib = Haemophilus 
ella vaccine; DTPa–Hep-B = combined diphtheria–ents of affected children at different
times of the day. Those successfully
contacted were invited to complete a
telephone questionnaire, which aimed
to ascertain a description of the reac-
tion, effect on the child’s behaviour,
time to recovery, other concurrent
adverse events, and the site of the DTPa
injection.
Statistical analysis
The rates of reports for local reactions,
skin rash and convulsions were com-
pared between the first dose and subse-
quent doses, and the 2 test was used to
calculate the significance of these differ-
ences. To assess the effect of primary
vaccinations with DTPw, the number of
reported events in children whose pri-
mary vaccinations were with DTPw was
compared with the number whose pri-
mary vaccinations were with DTPa by
means of 2 analysis.
RESULTS
Surveillance
In the study period, 581 reports of
adverse events after vaccination were
received. The annual rate of reports
received varied (ranging from 20
reports per 100 000 distributed vaccines
in 1999 to 44 per 100 000 in 1997), but
did not increase. Of the 209 local reac-
tions reported, 28 (13%) met the cri-
teria for reporting to ADRAC, and 138
were associated with the administration
of a pertussis-containing vaccine. Of
these, 100 (73%) were associated with
DTPa, 82 of which occurred after a
fourth dose (Box 3).
Box 4 documents adverse events after
receiving DTPa as the fourth dose, for
cohorts whose primary vaccinations
were with DTPw or DTPa.
Severity and outcomes
Between 1 January 1998 and 31
December 2000, 71 reports were
received of local reactions after the
fourth dose of DTPa. Parents were con-
tacted and completed the telephone
interview in 45 of these cases (63%); in
26 cases parents could not be contacted
either because details were incorrect or
contact attempts failed.MJA Vol 179 18 August 2003
RESEARCHThe median age of these 71 children
at the time of the fourth dose was 19.5
months (range, 18–48 months) and
their median age at the time of the
interview was 32 months (range, 19–93
months). There were no significant dif-
ferences with regard to sex or age at the
time of the fourth vaccination between
children whose parents could and could
not be contacted.
Of the 45 children whose parents
were contacted, 27 (60%) had the site
of administration of the DTP vaccine
documented, and this was the same site
as the reported local reaction. One child
received the DTP vaccine in the buttock
(not recommended in Australia), 36 in
the arm (the preferred site) and eight in
the anterolateral thigh. Forty-two of the
45 children had the administered vac-
cine recorded as DTPa, three had no
brand documented, and none had
DTPw documented.
All parents reported that swelling
occurred with the local reaction, and all
but one reported redness with it. The
median time to symptom onset was
19.3 hours (range, immediate to 72
3: Adverse events after acellular diph
pertussis and hepatitis B vaccine (D
31 December 2000
1
No. of doses of DTPa and 
DTPa–Hep-B administered
41 807
No. (rate)* of local reactions 2 (5)
Relative risk† (95% CI)
No. (rate) of skin rash reports 8 (19)
Relative risk† (95% CI)
No. (rate) of convulsions and HHE 7 (17)
Relative risk† (95% CI)
*Rate per 100 000 administered doses. † Compared wit
4: Adverse events after receiving DTP
(1 January 1997 to 31 December 1
N
Primary vaccinations at 2, 4, and 6 months
DTPw
DTPa
Relative risk (95% CI) of reaction after 
DTPa versus DTPw primary vaccinations
* P < 0.001 Fisher exact test. HHE = hypotonic hyporespMJA Vol 179 18 August 2003hours). The median durations of red-
ness and swelling were 75 hours (range,
24–168 hours) and 77 hours (range,
24–168 hours), respectively. All but one
reported complete recovery by the time
of review. In 10 of the 45 children
(22%), the local reaction met the case
definition for a report to ADRAC, and
eight of these (18%) had extensive limb
swelling.
DISCUSSION
Our surveillance data show that, after
the introduction of DTPa in South Aus-
tralia, the reported rates of a local reac-
tion following the fourth dose of DTPa
are 34 times higher than after the first
dose. This increased rate of local reac-
tion may reflect a true increase, or a
selective increase in reporting of adverse
events after the fourth dose. However,
we did not find the same trend for
reported skin rash, convulsions or hypo-
tonic hyporesponsive episodes after the
fourth dose of the same vaccine. In
addition, the number of reports of
theria–tetanus–pertussis (DTPa) and com
TPa–Hep-B) administration, according t
Dose number
2 3
41 529 41 585
3 (7) 5 (12)
1.51 (0.25–9.04) 2.51 (0.49–12.95)
5 (12) 5 (12)
0.63 (0.21–1.92) 0.63 (0.21–1.92) 1
1 (2) 0
0.14 (0.02–1.17) 0
h 1st dose. ‡ P < 0.001. HHE = hypotonic hyporesponsive 
a as a fourth dose in cohorts whose pri
998) or DTPa (1 June 1999 to 31 Dec
Number
o. DTPa 4th doses administered Local reactions
11 071 4 (36)
24 719 60 (243)
6.7 (2.4–18.5)*
onsive episode.adverse events per 100 000 distributed
vaccines received by SAICU was higher
in 1997 than in 2000. Therefore, ascer-
tainment bias is unlikely. Local reac-
tions are being reported in children who
have had primary vaccinations with
DTPa rather than DTPw. This might
explain why the initial surveillance data
indicated a lower rate of local reactions
following the fourth dose of DTPa. As
the surveillance database and ACIR reg-
ister were established in 1996, it was not
possible to compare the rates of local
reactions following the fourth and fifth
dose of DTPw with DTPa.
An increase in the frequency of local
reactions is recognised to occur with
booster doses of acellular pertussis vac-
cines.11,12 In a multicentre trial evaluating
1293 children who received a fourth dose
of DTPa vaccine at 15–20 months of age,
local reactions were less common with
DTPa than with DTPw, but more com-
mon with an increasing number of DTPa
doses and after DTPa primary vaccina-
tions (as compared with DTPw primary
vaccinations).11 No consistent pattern
was revealed for different DTPa vaccines.
bined acellular diphtheria–tetanus–
o dose number, 1 January 1997 to 
4 Total
41 459 166 380
71 (171) 81 (47)
36‡ (8.78–146)
8 (19) 26 (16)
.01 (0.38–2.69)
3 (7) 11 (7)
.43 (0.11–1.67)
episode. 
mary vaccinations were with DTPw 
ember 2000)
 (rate per 100000 administered doses)
Skin rash Convulsions and HHE
1 (10) 1 (10)
4 (16) 0
1.61 (0.18–14.2) —193
RESEARCHExtensive limb swelling after booster
doses of DTPa appears to occur in up to
one in 36 vacinees.5,12-15 Our surveil-
lance data indicate that there is still an
underreporting of extensive limb swell-
ing in South Australia.
It is not known if extensive limb swell-
ing represents a distinct pathological
entity or an extreme form of a local
reaction. Its rates may be correlated
with the diphtheria content of individ-
ual vaccines,14 or possibly to the
pertussis13 and aluminium content.14
DTPa for primary vaccinations is the
only identified risk factor for local reac-
tions and extensive limb swelling with
booster doses.14 A recent study has doc-
umented a direct association between
pre-booster antibody titres to diphtheria
and pertussis toxin, and large local reac-
tions in 4–6-year-old children receiving
a two component DTPa vaccine.15
Thus, parents and caregivers of chil-
dren receiving a booster dose of a DTPa
vaccine following DTPa primary vacci-
nations should be informed that there is
an increased risk of local reactions,
including extensive limb swelling. How-
ever, they should also be informed that
no significant sequelae have been
reported following these reactions.
Indeed, ADRAC recommends that chil-
dren who have had extensive limb swell-
ing with a fourth dose of DTPa should
be offered a fifth dose.16 Surveillance
for local reactions after vaccination
should continue to be widely promoted
in order to document the frequency of
fourth and fifth dose reactions. These
findings may have implications for the
number, timing and antigen content of
DTP booster vaccines included in the
vaccination schedule. A recent study
reporting that protection against pertus-
sis after a primary course may persist
until six years of age, may indicate that
the fourth dose of DTPa at 18 months
is no longer required.17 
Finally, prospective studies should be
initiated to investigate the pathogenesis
of local reactions. This should compare
the frequencies of local reactions to dif-
ferent DTPa vaccines, identify possible
risk factors, and establish the risk of
recurrence in those children who have
experienced a local reaction. Such meas-
ures are vital to ensure that vaccines are
safe, and that public confidence in per-
tussis vaccination remains high.194COMPETING INTERESTS
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